ClinicalTrials.gg

Sarcopenia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,330 studies for Sarcopenia across more than 10 countries. 419 are recruiting or about to start. 799 of them are mainly about Sarcopenia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 1,431 studies for Sarcopenia. How that becomes 1,329 here

This page counts the studies the registry files under Sarcopenia, and those it files under no condition that list Sarcopeniathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,431Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −17List Sarcopenia as a condition, but the registry did not file them under itMost often written as “Sarcopenia in Elderly” (8), “Age-Related Sarcopenia” (7), and “Pre-sarcopenia” (1). The registry filed them under other conditions only, most often Frailty (5) and Motor Activity (3).
  3. −85Match it another way84 name it in the title and 1 in a keyword.
  4. 1,329The count on this page23 of them list Sarcopenia in their own words; the registry filed them under no condition.

Status

Completed
629
Recruiting
247
Status unknown
158
Not yet recruiting
143
Active, not recruiting
66
Terminated
37

Phase

Phase 2
52
Phase 3
26
Phase 4
21
Phase 1
21
Early Phase 1
9

Where

United States
187
Turkey
130
Spain
99
Taiwan
96
China
82
France
78

Who develops what

Add Sarcopenia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 10 companies, 9 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Eli Lilly and HK inno.N here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
isomyosmineRecent, limited
Evidence
  • NCT05283486 · TNF Pharmaceuticals, Inc. · Phase 2 · comparator · “MYMD-1 1050mg” · registered Feb 2022
MyMD Pharmaceuticals, Inc.67% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Jun 2027 est.PLH-2301 · Pluto Inc. · Phase 2 main aimNCT07390552 A Study of PLH-2301 in Subjects With Sarcopenia — primary endpoint: Change from baseline in Short Physical Performance Battery (SPPB) total score · 168 enrolled
  • 22 Aug 2027 est.TJ0113 · Hangzhou PhecdaMed Co., Ltd. · Phase 2 main aimNCT07620938 Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia — primary endpoint: Change from baseline in gait speed on the 400-meter Walk Test at Week 26 · 204 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Sarcopenia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Androgens 2 open

Coming up

150studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 247 Sarcopenia studies recruiting now, 153 (62%) set no upper age limit and 32 (13%) stop at 75 or younger. 9 (4%) take children under 18. 10 (4%) are for women only and 5 (2%) for men only; 65 (26%) take healthy volunteers.

Recruiting studies that take each age, of 247
AgeWomenMen
108 (3%)8 (3%)
18109 (44%)105 (43%)
30124 (50%)120 (49%)
40137 (55%)134 (54%)
50160 (65%)155 (63%)
65225 (91%)219 (89%)
75220 (89%)216 (87%)
85189 (77%)186 (75%)

Across all 1,330 studies, recruiting or not: 16% stop at 75 or younger and 7% at 65; 3% take children; 7% are for women only and 6% for men only; 41% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Sarcopenia studies take

Of 20 phase 2 interventional studies under Sarcopenia, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 237 mo19–39 · 20 studies——
Interventional, no phase18 mo8–34 · 505 studies—18 mo8–35 · 494 studies
Observational26 mo12–63 · 193 studies—26 mo12–63 · 191 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Results posted1

Newly registered21

Show 16 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,330. Browse all 1,330 → or search them.